- |||||||||| hydrocortisone / Generic mfg., epinephrine / Generic mfg.
Clinical, Journal: Physiologic effects of stress dose corticosteroids in in-hospital cardiac arrest (CORTICA): A randomized clinical trial. (Pubmed Central) - Jun 4, 2022 P1/2 We conducted a two-center, randomized, double-blind trial of patients with adrenaline (epinephrine)-requiring cardiac arrest...Postresuscitation shock was treated with hydrocortisone 240 mg daily for 7 days maximum and gradual taper (steroids group), or saline-placebo (control group)...There was no between-group difference in body temperature, echocardiographic variables, prefrontal blood flow index/cerebral autoregulation, organ failure-free days, and hazard for poor in-hospital/functional outcome, and adverse events (P = 0.08->0.99). Our results do not support the use of low-dose corticosteroids in in-hospital cardiac arrest.Trial Registration:ClinicalTrials.gov number: NCT02790788 ( https://www.clinicaltrials.gov ).
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 3, 2022 P2, N=58, Active, not recruiting, In conclusion, Isa-Kd provides a consistent benefit vs Kd in elderly patients, with a manageable safety profile, and represents a new treatment option for patients with relapsed MM, independent of age. Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- |||||||||| Zyesami IV (aviptadil intravenous) / Relief Therap, NRx Pharma
Enrollment closed: TESICO: ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (clinicaltrials.gov) - Jun 3, 2022 P3, N=640, Active, not recruiting, Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Recruiting --> Active, not recruiting
- |||||||||| 19 Year Old Wrestler With Altered Mental Status (31A) - Jun 2, 2022 - Abstract #ACSM2022ACSM_1323;
CT 11/3: Interval development of increased sulcal crowding of the bilateral cerebral convexities concerning for mild diffuse cerebral edema. MRI 10/18: Subtle cortical edema is suggested diffusely that can be seen with encephalitis versus seizure activity.
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) - Jun 2, 2022 P1/2, N=66, Recruiting, MRI 10/18: Subtle cortical edema is suggested diffusely that can be seen with encephalitis versus seizure activity. Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2027 --> Oct 2027
- |||||||||| dexamethasone / Generic mfg., clonidine / Generic mfg., epinephrine / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: RCT Comparing ESPB Solutions in Breast Surgery (clinicaltrials.gov) - Jun 2, 2022 P2, N=75, Recruiting, Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2027 --> Oct 2027 Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Dec 2022
- |||||||||| hydrocortisone / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Neuroimaging Mechanisms by Which Memory and Glucocorticoids Promote Risky Drinking (clinicaltrials.gov) - Jun 2, 2022 P1, N=27, Completed, Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Apr 2022 --> Dec 2022 Recruiting --> Completed | Trial completion date: Jun 2023 --> Mar 2022 | Trial primary completion date: Jun 2023 --> Mar 2022
- |||||||||| Opdivo (nivolumab) / BMS, Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment closed, Enrollment change, Trial primary completion date, Oncolytic virus: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 1, 2022 P1, N=23, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=62 --> 23 | Trial primary completion date: May 2022 --> May 2023
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Checkpoint inhibition, Checkpoint block, Metastases: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (clinicaltrials.gov) - Jun 1, 2022 P1, N=16, Suspended, Recruiting --> Active, not recruiting | N=62 --> 23 | Trial primary completion date: May 2022 --> May 2023 Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
- |||||||||| dexamethasone / Generic mfg.
Trial completion: CIDEX: Dexamethasone-Eluting Cochlear Implant Electrode (clinicaltrials.gov) - Jun 1, 2022 P=N/A, N=10, Completed, Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023 Active, not recruiting --> Completed
- |||||||||| dexamethasone / Generic mfg.
Clinical, Journal: Responding to COVID-19 Through Interhospital Resource Coordination: A Mixed-Methods Evaluation. (Pubmed Central) - May 31, 2022 Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jun 2021 With standardized communication, interhospital transfers can be a safe and effective method of cohorting COVID-19 patients, are well received by health care providers, and have the potential to improve care quality.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Protective effect of Naringin ameliorates TNBS-induced colitis in rats via improving antioxidant status and pro-inflammatory cytokines. (Pubmed Central) - May 31, 2022 Forty-two male Wistar rats were divided into seven groups like Normal Control (NC), Ethanol Control (EC), Disease Control (DC), NG 20 (20 mg/kg, p.o.), NG 40 (40 mg/kg, p.o.), NG 80 (80 mg/kg, p.o.), and Dexamethasone (DEX) (2 mg/kg, p.o.)...Our results demonstrated that NG treatment attenuated pathologic changes of TNBS-induced colitis in rats through restoring colonic damage and reducing inflammatory response in the colon tissue. Thus, NG might be considered as an effective candidate for the treatment of UC patients.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Emerging treatment for congenital adrenal hyperplasia. (Pubmed Central) - May 31, 2022 Trials of corticotropin releasing hormone receptor antagonists and androgen biosynthesis inhibitors are currently underway. The author believes that trials of gene therapy for CAH are premature.
- |||||||||| dexamethasone / Generic mfg.
Trial completion date: Anosmia and / or Ageusia and Early Corticosteroid Use (clinicaltrials.gov) - May 31, 2022 P4, N=300, Recruiting, Studies stratifying DST non-suppressors according to established dosage-regimens in somatic settings are needed to fully elucidate the putative contribution of HPA-axis dysregulation to EA. Trial completion date: May 2022 --> Oct 2022
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Trial primary completion date: ACTIV-6: COVID-19 Study of Repurposed Medications (clinicaltrials.gov) - May 30, 2022 P3, N=15000, Recruiting, Trial completion date: May 2022 --> Oct 2022 Trial primary completion date: Dec 2022 --> Mar 2023
|